As shown in Figure 3C, patients whose tumours had high LIG1/high XRCC1 had worse PFS after platinum-based chemotherapy compared to patients whose tumours had low LIG1/low XRCC1 co-expression. The gene discussed is XRCC1; the disease is neoplasm.